| Wissenschaftl. Titel | A Phase 3, Multicenter, Randomized, Open-label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non–Small Cell Lung Cancers, Negative for PD-L1, and Positive for KRAS p.G12C (CodeBreaK 202) |
| Erkrankung |
Thorax:
Nicht-kleinzelliges Lungenkarzinom:
Erstlinie
|
| Molekularer Marker |
KRASG12C |
| Kurzprotokoll | Kurzprotokoll |
| Links | Weiterführende Informationen (NIH) |
erstellt 19.04.2024 Data entry III CCP
geändert 19.04.2024 Data entry III CCP